EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSG00000145675
Gene: PIK3R1
Gene Synonyms: GRB1,P85,P85-ALPHA,P85ALPHA
26 APIs:
149 Enzyme and pathways 9 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSG00000105647
Gene: PIK3R2
Gene Synonyms: P85,P85-BETA,P85B,P85BETA
26 APIs:
93 Enzyme and pathways 9 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSG00000117461
Gene: PIK3R3
Gene Synonyms: P55
26 APIs:
48 Enzyme and pathways 7 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSG00000141506
Gene: PIK3R5
Gene Synonyms: P101,P101-PI3K
26 APIs:
15 Enzyme and pathways 8 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phospholipase A2 Group Iia

Ensembl ID : ENSG00000188257
Gene: PLA2G2A
Gene Synonyms: PLA2B,PLA2L
2 APIs:
13 Enzyme and pathways 8 Cross references
169 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phospholipase A2 Group V

Ensembl ID : ENSG00000127472
Gene: PLA2G5
Gene Synonyms:
1 APIs:
10 Enzyme and pathways 8 Cross references
116 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phospholipase A2 Group Vii

Ensembl ID : ENSG00000146070
Gene: PLA2G7
Gene Synonyms: LDL-PLA2,PAFAH
2 APIs:
3 Enzyme and pathways 8 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phospholipase A2 Group X

Ensembl ID : ENSG00000069764
Gene: PLA2G10
Gene Synonyms: GXPLA2
1 APIs:
10 Enzyme and pathways 7 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSG00000159131
Gene: GART
Gene Synonyms: GARS-AIRS-GART,PGFT,PRGS
1 APIs:
4 Enzyme and pathways 7 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Plasminogen

Ensembl ID : ENSG00000122194
Gene: PLG
Gene Synonyms:
12 APIs:
13 Enzyme and pathways 9 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Plasminogen Activator, Tissue Type

Ensembl ID : ENSG00000104368
Gene: PLAT
Gene Synonyms:
1 APIs:
5 Enzyme and pathways 8 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Activating Factor Receptor

Ensembl ID : ENSG00000169403
Gene: PTAFR
Gene Synonyms:
2 APIs:
14 Enzyme and pathways 7 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).